专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06423729B1 Therapeutic or prophylactic agent for glomerulopathy 失效
标题翻译：肾小球病的治疗或预防剂
公开(公告)号：US06423729B1
公开(公告)日：2002-07-23
申请号：US09462001
申请日：1999-12-30
申请人： Hidetake Kurihara , Fumihiko Watanabe , Yoshinori Tamura , Toshihiro Sinosaki
发明人： Hidetake Kurihara , Fumihiko Watanabe , Yoshinori Tamura , Toshihiro Sinosaki
IPC分类号： C07D33318
CPC分类号： C07C311/29 , A61K31/18 , A61K31/381 , A61K31/404 , A61K31/41 , A61K31/421 , A61K31/4245 , C07C311/19 , C07C311/44 , C07C311/46 , C07C323/62 , C07D209/16 , C07D257/04 , C07D271/06 , C07D333/18 , C07D403/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04
摘要： A composition for treating or preventing glomerulopathy which contains a compound of the formula (I): wherein, for example, R1 and R2 are each independently hydrogen atom, optionally substituted lower alkyl, optionally substituted aralkyl, etc.; R3 is 1,4-phenylene and 2,5-thiophendiyl; R4 is the substituents represented by the formula, etc.: wherein R6 is hydrogen atom, optionally substituted amino, etc.; and Y is NHOH or OH, its optically active substance, their pharmaceutically acceptable salt, or hydrate thereof.
摘要翻译：用于治疗或预防肾小球病的组合物，其含有式（I）化合物：其中，例如，R 1和R 2各自独立地为氢原子，任选取代的低级烷基，任选取代的芳烷基等; 亚苯基和2,5-噻吩二基; R4是由式等表示的取代基：其中R6是氢原子，任选取代的氨基等; 和Y是NHOH或OH，其光学活性物质，其药学上可接受的盐或水合物。

2. 发明授权

US06878739B2 Composition for treating or preventing glomerulopathy 失效
标题翻译：用于治疗或预防肾小球病的组合物
公开(公告)号：US06878739B2
公开(公告)日：2005-04-12
申请号：US10162865
申请日：2002-06-06
申请人： Hidetake Kurihara , Fumihiko Watanabe , Yoshinori Tamura , Toshihiro Sinosaki
发明人： Hidetake Kurihara , Fumihiko Watanabe , Yoshinori Tamura , Toshihiro Sinosaki
IPC分类号： A61K31/18 , A61K20060101 , A61K31/38 , A61K31/381 , A61K31/404 , A61K31/405 , A61K31/41 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/4245 , A61P13/12 , A61P43/00 , C07C311/19 , C07C311/37 , C07C311/39 , C07D209/04 , C07D209/20 , C07D257/04 , C07D263/32 , C07D271/06 , C07D333/12 , C07D333/18 , C07D333/34 , C07D403/12 , C07D409/04 , C07D411/04 , C07D413/04
CPC分类号： C07C311/29 , A61K31/18 , A61K31/381 , A61K31/404 , A61K31/41 , A61K31/421 , A61K31/4245 , C07C311/19 , C07C311/44 , C07C311/46 , C07C323/62 , C07D209/16 , C07D257/04 , C07D271/06 , C07D333/18 , C07D403/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04
摘要： A composition for treating or preventing glomerulopathy which contains a compound of the formula (I): wherein, for example, R1 and R2 are each independently hydrogen atom, optionally substituted lower alkyl, optionally substituted aralkyl, etc.; R3 is 1,4-phenylene and 2,5-thiophendiyl; R4 is the substituents represented by the formula, etc.: wherein R5 is hydrogen atom, optionally substituted amino, etc.; and Y is NHOH or OH, its optically active substance, their pharmaceutically acceptable salt, or hydrate thereof.
摘要翻译：一种用于治疗或预防肾小球病的组合物，其含有式（I）化合物：其中，例如R 1和R 2各自独立地为氢原子，任选取代的低级烷基，任选取代的芳烷基等; R 3是1,4-亚苯基和2,5-噻吩二基; R 4是由式等表示的取代基：其中R 5是氢原子，任选取代的氨基等; 和Y是NHOH或OH，其光学活性物质，其药学上可接受的盐或水合物。

3. 发明授权

US07825146B2 Sulfonamide derivative having isoxazole ring 失效
标题翻译：具有异恶唑环的磺酰胺衍生物
公开(公告)号：US07825146B2
公开(公告)日：2010-11-02
申请号：US10565948
申请日：2004-07-28
申请人： Fumihiko Watanabe , Naoki Yoshikawa , Yoshinori Tamura
发明人： Fumihiko Watanabe , Naoki Yoshikawa , Yoshinori Tamura
IPC分类号： A61K31/422
CPC分类号： C07D261/08 , A61K31/42
摘要： A compound represented by the general formula (I-A): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a group represented by the formula: R6 is optionally substituted aryl and the like, its optically active substance, their pharmaceutically acceptable salt, or a solvate thereof; and a metalloproteinase inhibitor containing them.
摘要翻译：由通式（I-A）表示的化合物：其中R1是羟基等; R2是任选取代的低级烷基等; R3是氢原子等; R4是任选取代的亚芳基等; R5是由下式表示的基团：R6是任选取代的芳基等，其光学活性物质，其药学上可接受的盐或其溶剂化物; 和含有它们的金属蛋白酶抑制剂。

4. 发明申请

US20060183770A1 Sulfonamide derivative having isoxazole ring 失效
标题翻译：具有异恶唑环的磺酰胺衍生物
公开(公告)号：US20060183770A1
公开(公告)日：2006-08-17
申请号：US10565948
申请日：2004-07-28
申请人： Fumihiko Watanabe , Naoki Yoshikawa , Yoshinori Tamura
发明人： Fumihiko Watanabe , Naoki Yoshikawa , Yoshinori Tamura
IPC分类号： A61K31/4709 , A61K31/454 , A61K31/42 , C07D413/02
CPC分类号： C07D261/08 , A61K31/42
摘要： A compound represented by the general formula (I-A): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a group represented by the formula: R6 is optionally substituted aryl and the like, its optically active substance, their pharmaceutically acceptable salt, or a solvate thereof; and a metalloproteinase inhibitor containing them.
摘要翻译：由通式（I-A）表示的化合物：其中R 1是羟基等; R 2是任选取代的低级烷基等; R 3是氢原子等; R 4是任选取代的亚芳基等; R 5是由下式表示的基团：R 6是任选取代的芳基等，其光学活性物质，其药学上可接受的盐或其溶剂化物; 和含有它们的金属蛋白酶抑制剂。

5. 发明申请

US20080119513A1 Sulfonamide Derivative Selectively Inhibiting Mmp-13 审中-公开
标题翻译：磺酰胺衍生物选择性抑制Mmp-13
公开(公告)号：US20080119513A1
公开(公告)日：2008-05-22
申请号：US11574801
申请日：2004-09-06
申请人： Fumihiko Watanabe , Yoshinori Tamura , Naoki Yoshikawa
发明人： Fumihiko Watanabe , Yoshinori Tamura , Naoki Yoshikawa
IPC分类号： A61K31/195 , C07C317/14 , C07D209/08 , A61K31/47 , A61P35/00 , A61P31/12 , A61P19/02 , A61K31/404 , C07D215/06
CPC分类号： C07D333/34 , C07C311/19 , C07C311/29 , C07C311/42 , C07C311/46 , C07C323/58 , C07C2601/08 , C07C2601/14 , C07D209/18 , C07D215/12 , C07D307/84 , C07D309/08 , C07D333/62
摘要： It is considered that MMP-13 inhibitors contribute to the treatment or prevention against the diseases caused by or related to activity of MMP-13, especially osteoarthritis (OA). Therefore, the development of MMP-13 inhibitors has been desired.A compound represented by the general formula (I): wherein Z is 1,4-phenylene and the like; R1 is hydroxy and the like; R2 is hydrogen atom, optionally substituted lower alkyl, and the like; R12 is hydrogen atom; or R2 and R12 taken together with the adjacent carbon atom may form a ring; R3 is hydrogen atom, optionally substituted lower alkyl, and the like; R4 is halogen, lower alkyl, and the like; m is 0, 1, or 2; X is a bond, —C≡C—, and the like; Y is optionally substituted phenyl, optionally substituted naphthyl, and the like, its optically active substance, their pharmaceutically acceptable salt, or a solvate thereof.
摘要翻译：认为MMP-13抑制剂有助于治疗或预防由MMP-13，特别是骨关节炎（OA）的活动引起的或与其相关的疾病。因此，期望MMP-13抑制剂的发展。由通式（I）表示的化合物：其中Z是1,4-亚苯基等; R 1是羟基等; R 2是氢原子，任选取代的低级烷基等; R 12是氢原子; 或R 2和R 12与相邻碳原子一起可以形成环; R 3是氢原子，任选取代的低级烷基等; R 4是卤素，低级烷基等; m为0,1或2; X是键，-C≡C-等; Y是任选取代的苯基，任选取代的萘基等，其光学活性物质，其药学上可接受的盐或其溶剂化物。

6. 发明授权

US06897237B2 MMP-12 inhibitors 失效
标题翻译： MMP-12抑制剂
公开(公告)号：US06897237B2
公开(公告)日：2005-05-24
申请号：US10257478
申请日：2001-04-23
申请人： Yozo Hori , Fumihiko Watanabe , Hiroshige Tsuzuki , Shingo Furue , Yoshinori Tamura
发明人： Yozo Hori , Fumihiko Watanabe , Hiroshige Tsuzuki , Shingo Furue , Yoshinori Tamura
IPC分类号： A61P11/00 , A61P43/00 , C07C311/19 , C07C311/29 , C07C311/46 , C07C323/58 , C07D209/20 , C07D257/04 , C07D271/06 , C07D271/10 , C07D271/107 , C07D333/34 , A61K31/192 , A61K31/215 , C07C69/612
CPC分类号： C07D257/04 , C07C311/19 , C07C311/29 , C07C311/46 , C07C323/58 , C07D209/20 , C07D271/06 , C07D271/107 , C07D333/34
摘要： A compound of the formula (I): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is —C≡C— and the like; R6 is optionally substituted naphtyl and the like its optically active substance, its prodrug, their pharmaceutically acceptable salt, or solvate thereof.
摘要翻译：式（I）的化合物：其中R 1是羟基等; R 2是任选取代的低级烷基等; R 3是氢原子等; R 4是任选取代的亚芳基等; R 5是-C≡C-等; R 6是任选取代的萘基等，其光学活性物质，其前药，其药学上可接受的盐或溶剂化物。

7. 发明授权

US06495578B1 Sulfonamide derivatives having oxadiazole rings 失效
标题翻译：具有恶二唑环的磺酰胺衍生物
公开(公告)号：US06495578B1
公开(公告)日：2002-12-17
申请号：US09959008
申请日：2001-10-17
申请人： Fumihiko Watanabe , Yoshinori Tamura , Yasuhiko Fujii
发明人： Fumihiko Watanabe , Yoshinori Tamura , Yasuhiko Fujii
IPC分类号： A61K314196
CPC分类号： C07D413/04
摘要： Sulfonamide derivatives having a matrix metalloprotease inhibiting effect, which are compounds represented by general formula (I), optical isomers of the same, pharmaceutically acceptable salts of both, or solvates of them: wherein R1 and R2 are each independently hydrogen atom, optionally substituted lower alkyl or the like; R3 is optionally substituted aryl, optionally substituted heteroaryl or the like; X is —CH═CH—, —O—, or —S—; Y is NHOH, hydroxy, or lower alkyloxy.
摘要翻译：具有基质金属蛋白酶抑制作用的磺酰胺衍生物，其为通式（I）表示的化合物，其光学异构体，它们的药学上可接受的盐或它们的溶剂合物：其中R1和R2各自独立地为氢原子，任选取代的低级烷基等; R3是任选取代的芳基，任选取代的杂芳基等; X是-CH = CH-，-O-或-S-; Y是NHOH，羟基或低级烷氧基。

8. 发明授权

US06949566B2 Thiazole and oxazole derivatives 失效
标题翻译：噻唑和恶唑衍生物
公开(公告)号：US06949566B2
公开(公告)日：2005-09-27
申请号：US10381280
申请日：2001-09-28
申请人： Fumihiko Watanabe , Yoshinori Tamura
发明人： Fumihiko Watanabe , Yoshinori Tamura
IPC分类号： A61P9/04 , A61P11/00 , A61P13/12 , A61P19/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D263/32 , C07D277/26 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/14 , A61K31/423 , A61K31/428 , C07D263/57 , C07D277/66 , C07D413/12
CPC分类号： C07D413/06 , C07D263/32 , C07D277/26 , C07D417/04 , C07D417/06 , C07D417/14
摘要： A compound of the formula (I): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a group represented by the formula: and the like; R6 is optionally substituted aryl and the like, its optically active substance, its prodrug, their pharmaceutically acceptable salt, or solvate thereof and metalloproteinase inhibitors containing them.
摘要翻译：式（I）的化合物：其中R 1是羟基等; R 2是任选取代的低级烷基等; R 3是氢原子等; R 4是任选取代的亚芳基等; R 5是由下式表示的基团：等等; R 6是任选取代的芳基等，其光学活性物质，其前药，其药学上可接受的盐或溶剂合物和含有它们的金属蛋白酶抑制剂。

9. 发明申请

US20090069304A1 MMP-13 SELECTIVE INHIBITOR 审中-公开
标题翻译： MMP-13选择性抑制剂
公开(公告)号：US20090069304A1
公开(公告)日：2009-03-12
申请号：US12281216
申请日：2007-03-01
申请人： Mikayo Hayashi , Fumihiko Watanabe
发明人： Mikayo Hayashi , Fumihiko Watanabe
IPC分类号： A61K31/5513 , C07D243/08 , C07D241/04 , A61K31/4965
CPC分类号： C07D209/86 , C07D211/96 , C07D241/04 , C07D243/08 , C07D295/22
摘要： Since it is thought that if the activity of MMP-13 can be inhibited, this will largely contribute to improvement or prevention of progession of pathological states, particularly, osteoarthritis (OA), resulting from or associated with the MMP-13 activity, the development of MMP-13 inhibitors is anticipated. There are provided a compound represented by the general formula (I): wherein R1 is optionally substituted aryl etc.; Z is C1-C5 alkylene which may be substituted and may be interrupted with a substituent selected from Substituent group a etc.; A is the formula: (R6 and R7 are each independently halogen, lower alkyl etc.; m and n are each independently 0, 1, or 2); R2 is a hydrogen atom, optionally substituted lower alkyl etc.; R3 is a hydrogen atom, optionally substituted lower alkyl etc.; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxy, lower alkyloxy etc.), or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof, and a pharmaceutical composition containing it as an active ingredient, which has the MMP-13 inhibiting activity.
摘要翻译：由于认为如果可以抑制MMP-13的活性，这将大大有助于改善或预防由MMP-13活性引起或与MMP-13活性相关的病理状态，特别是骨关节炎（OA），发展的MMP-13抑制剂。提供由通式（I）表示的化合物：其中R 1是任选取代的芳基等; Z是可以被取代的C1-C5亚烷基，可以被选自取代基组a等的取代基中断; A是下式：（R 6和R 7各自独立地为卤素，低级烷基等; m和n各自独立地为0,1或2）; R2是氢原子，任选取代的低级烷基等; R3是氢原子，任选取代的低级烷基等; R4是氢原子; 或者R 3和R 4可以与相邻的碳原子一起与环一起取代; R5是羟基，低级烷氧基等）或光学活性异构体，其药学上可接受的盐或溶剂合物，以及含有其作为活性成分的具有MMP-13抑制活性的药物组合物。

10. 发明授权

US5206666A Ink jet recording apparatus 失效
标题翻译：喷墨记录装置
公开(公告)号：US5206666A
公开(公告)日：1993-04-27
申请号：US617365
申请日：1990-11-23
申请人： Fumihiko Watanabe , Takeshi Ono
发明人： Fumihiko Watanabe , Takeshi Ono
IPC分类号： B41J2/165 , B41J13/00 , B41J13/14 , B41J25/316
CPC分类号： B41J2/16588 , B41J13/14 , B41J2/16585 , B41J25/316 , B41J2202/21
摘要： An ink jet recording apparatus includes a full-line type recording head having plural ejection outlets; a shaft for rotatably supporting the recording head between a recording position in which the ink is ejected in a non-vertical direction and a non-recording position in which the ink is ejected substantially vertically; a device, disposed adjacent a recording position of the recording head, contributable to feeding of the recording material; and a positioning plate press-contacted to the contributable device to confine a recording surface of the recording material in cooperation with the contributable device.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式